BRCA2 Gene Mutation: Cancer Risks, Testing, and Next Steps

BRCA2 stands for BReast CAncer gene 2. It is a tumor suppressor gene located on chromosome 13 that plays a critical role in repairing double-strand breaks in your DNA. When your cells divide and copy their genetic material, mistakes can occur. The BRCA2 protein works through a process called homologous recombination to fix these errors before they accumulate and lead to uncontrolled cell growth.

When someone inherits a mutation in the BRCA2 gene, this DNA repair process is impaired. Damaged DNA may go unrepaired, increasing the chance that cells accumulate errors and eventually become cancerous. BRCA2 mutations follow an autosomal dominant inheritance pattern, which means you only need one mutated copy of the gene — inherited from either parent — for your cancer risk to be significantly elevated.

Approximately 1 in 400 to 1 in 500 people in the general population carry a BRCA2 mutation. The prevalence is notably higher in certain groups, including roughly 1 in 40 individuals of Ashkenazi Jewish descent. BRCA2 is classified as a high-risk gene, meaning carriers face substantially elevated cancer risk compared to the general population. While BRCA2 generally carries slightly lower breast cancer risk than BRCA1, it is associated with higher risk for certain other cancers, including pancreatic cancer and prostate cancer. Other genes in the DNA repair pathway, such as PALB2, work directly alongside BRCA2 to carry out repairs. To learn whether genetic testing may be right for you, see our guide on hereditary cancer screening.

A BRCA2 mutation raises the risk for several cancer types. Understanding these risks can help you and your healthcare team build the right screening and prevention plan.

Breast cancer (women)

• General population lifetime risk: approximately 13%
• BRCA2 mutation carriers: 45–69% lifetime risk
• Risk level depends on the specific variant and family history
• BRCA2-associated breast cancers are more often hormone receptor-positive, which means more treatment options are typically available

Ovarian cancer

• General population lifetime risk: approximately 1–2%
• BRCA2 mutation carriers: 17–23% lifetime risk
• This is lower than BRCA1-associated ovarian cancer risk but still significantly elevated

Male breast cancer

• General population lifetime risk for men: approximately 0.1%
• BRCA2 male carriers: 5–10% lifetime risk
• BRCA2 is the most common cause of hereditary male breast cancer

Pancreatic cancer

• BRCA2 carriers face approximately 3–5× elevated risk
• Estimated lifetime risk of approximately 5–7%
• Additional surveillance may be recommended for carriers with a family history of pancreatic cancer

Prostate cancer

• BRCA2 carriers have elevated risk for aggressive prostate cancer, especially before age 65
• Earlier and more frequent screening is recommended for male carriers

Melanoma

• Some studies show elevated melanoma risk in BRCA2 carriers
• Annual skin exams are recommended

Key takeaway: BRCA2 affects more cancer types than BRCA1 and carries a specific, significant risk for men. Both women and men with a BRCA2 mutation should work with their healthcare team to build a personalized screening plan.

BRCA1 and BRCA2 are often discussed together because both are high-risk genes involved in DNA repair. However, they carry different risk profiles, and understanding these differences matters for screening and prevention decisions.

• Ovarian cancer risk: BRCA1 carriers generally face higher ovarian cancer risk (39–44%) compared to BRCA2 carriers (17–23%). This difference affects the recommended timing for risk-reducing surgery.
• Pancreatic and prostate cancer: BRCA2 mutations carry higher risk for pancreatic cancer and aggressive prostate cancer than BRCA1 mutations. Male BRCA2 carriers in particular should discuss early prostate screening with their doctor.
• Male breast cancer: BRCA2 is the leading cause of hereditary male breast cancer. While BRCA1 also increases male breast cancer risk, BRCA2 carriers face a notably higher lifetime risk (5–10%).
• Breast cancer subtype: BRCA2-associated breast cancers are more often hormone receptor-positive (ER+/PR+), which generally means more treatment options are available. BRCA1-associated cancers are more often triple-negative.
• Screening timing: Both genes warrant enhanced screening, but the specifics differ. For example, risk-reducing salpingo-oophorectomy is typically recommended at age 35–40 for BRCA1 carriers and age 40–45 for BRCA2 carriers.

Both BRCA1 and BRCA2 are included in standard multi-gene panel tests. For a detailed overview of the testing process and what to expect, see our complete guide to hereditary cancer genetic testing.

Enhanced screening does not prevent cancer, but it increases the chances of catching it early — when treatment is most effective. NCCN guidelines provide specific recommendations for BRCA2 carriers. Your provider may adjust these based on your personal and family history.

Women with a BRCA2 mutation

• Annual breast MRI starting at age 25–30
• Annual mammogram starting at age 30
• Clinical breast exam every 6–12 months
• Risk-reducing salpingo-oophorectomy (RRSO) typically recommended at age 40–45 — later than BRCA1 due to the later average onset of BRCA2-associated ovarian cancer
• Discussion of risk-reducing mastectomy based on personal risk assessment
• Chemoprevention options (tamoxifen, aromatase inhibitors) may be appropriate for some carriers

Men with a BRCA2 mutation

• Monthly breast self-examination starting at age 35
• Annual clinical breast exam starting at age 35
• Prostate cancer screening (PSA and clinical exam) starting at age 40
• Consider pancreatic cancer surveillance if there is a family history of pancreatic cancer
• Annual dermatologic examination for melanoma screening

All BRCA2 carriers

• Cascade testing: first-degree relatives (parents, siblings, children) should be offered genetic testing, as each has a 50% chance of carrying the same mutation
• Keep your entire healthcare team informed about your BRCA2 status so screening and treatment decisions can be tailored to your risk profile

Important: These are general guidelines. A licensed genetic counselor can help you build a personalized screening plan based on your specific variant, family history, and personal preferences.

A positive BRCA2 result means that genetic testing found a pathogenic (harmful) variant in your BRCA2 gene. This is important information, but it is not a cancer diagnosis. It means your lifetime cancer risk is elevated compared to the general population, and it opens the door to proactive steps that can significantly reduce that risk.

Not all BRCA2 test results are the same. There are three main types:

• Pathogenic or likely pathogenic variant: A clearly harmful mutation was found. This is what most people mean by “testing positive.” It confirms elevated cancer risk and triggers specific screening and prevention recommendations.
• Variant of uncertain significance (VUS): A variant was found, but there is not yet enough evidence to classify it as harmful or harmless. A VUS does not change your screening plan. Over time, as more research is done, the variant may be reclassified. A genetic counselor can explain what a VUS means for your specific situation.
• Negative (no variant found): No harmful BRCA2 variant was detected. This is reassuring but does not eliminate all cancer risk, especially if there is a strong family history. Your doctor may recommend additional testing or screening based on other risk factors.

A positive result is not a reason to panic — it is a reason to act. Knowing your BRCA2 status empowers you and your healthcare team to choose the right screening schedule, consider risk-reducing options, and identify family members who may also benefit from testing. For a detailed explanation of result types, see our guide on understanding your genetic test results. For specific next steps after a positive result, see what to do after a positive genetic test.

If you have received a positive BRCA2 genetic test result, here are the steps to take:

1. Share your results with your doctor. Your primary care physician, OB/GYN, or oncologist should know about your BRCA2 status. This information directly affects your screening plan, treatment options, and ongoing care. Ask for a referral to a genetics specialist if you do not already have one.
2. See a genetic counselor. A licensed genetic counselor can interpret your specific BRCA2 variant in the context of your sex, age, and family history. BRCA2 implications differ between women and men, and a counselor can help you understand exactly what your result means for you. They can also help you create a personalized risk management plan.
3. Tell your first-degree relatives. Each of your parents, siblings, and children has a 50% chance of carrying the same BRCA2 mutation. Sharing your result gives them the opportunity to get tested and begin appropriate screening if they also carry the variant. Cascade testing is one of the most effective ways to protect your family.
4. Start your recommended screening schedule. Follow the gender-specific screening guidelines outlined above, adjusted for your personal and family history. For women, this typically includes annual breast MRI and mammogram. For men, this includes prostate screening and breast exams. Early detection dramatically improves outcomes.
5. Discuss risk-reduction options with a specialist. Depending on your situation, your medical team may recommend chemoprevention (medications that lower cancer risk), risk-reducing surgery, or a combination of enhanced surveillance and lifestyle modifications. These decisions are deeply personal and should be made with full information and support.

A positive BRCA2 result can feel overwhelming, but it is ultimately empowering. You now have information that most people do not — and that information enables you to take concrete steps to protect your health. If you have not been tested yet and want to find out whether hereditary cancer genetic testing is right for you, our free eligibility screener can help.

If a relative has received a positive BRCA2 result, learn about what a family member's positive BRCA result means for you.

Ready to find out if you qualify for hereditary cancer testing? Learn more about BRCA testing eligibility and how to get started.

NCCN recommends BRCA2 genetic testing for individuals with a personal or family history of breast cancer before age 50, ovarian cancer at any age, male breast cancer, pancreatic cancer, metastatic prostate cancer, or multiple breast cancers. Testing is also indicated for individuals of Ashkenazi Jewish ancestry with breast or ovarian cancer, or when a known BRCA2 mutation exists in the family.

BRCA2 mutations follow autosomal dominant inheritance, meaning each first-degree relative has a 50% chance of carrying the same mutation. Both sons and daughters can inherit and be affected. Male carriers face increased prostate, breast, and pancreatic cancer risks and can pass the mutation to their children. NCCN strongly recommends cascade testing for all blood relatives once a BRCA2 mutation is identified, as early detection and risk management can significantly improve outcomes.